FDA approves GSK’s JAK inhibitor for rare blood cancer after three-month delay

The FDA approved a new JAK inhibitor, momelotinib, from GSK for adults with the rare bone marrow cancer myelofibrosis who also have anemia. The approval marks a major turnaround for the drug, which had failed earlier studies and was dumped by Gilead for a mere $3 million in 2018.

Click here to view original post